Literature DB >> 28051796

 Differences in hepatic expression of iron, inflammation and stress-related genes in patients with nonalcoholic steatohepatitis.

Priya Handa1, Akhila L Vemulakonda1, Bryan D Maliken2, Vicki Morgan-Stevenson3, James E Nelson2, Barjinder K Dhillon2, Kelly A Hennessey1, Rohit Gupta2, Matthew M Yeh4, Kris V Kowdley1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. We have previously shown that hepatic reticuloendothelial system (RES) iron deposition is associated with an advanced degree of nonalcoholic steatohepatitis (NASH) in humans. In this study, we aimed to determine differentially expressed genes related to iron overload, inflammation and oxidative stress pathways, with the goal of identifying factors associated with NASH progression. Seventy five patients with NAFLD were evaluated for their biochemical parameters and their liver tissue analyzed for NASH histological characteristics. Gene expression analysis of pathways related to iron homeostasis, inflammation and oxidative stress was performed using real-time PCR. Gene expression was compared between subjects based on disease status and presence of hepatic iron staining. We observed increased gene expression of hepcidin (HAMP) (2.3 fold, p = 0.027), transmembrane serine proteinase 6 (TMPRSS6) (8.4 fold, p = 0.003), signal transducer and activator of transcription 3 (STAT3) (5.5 fold, p = 0.004), proinflammatory cytokines; IL-1? (2.7 fold, p = 0.046) and TNF-? (3.8 fold, p = 0.001) in patients with NASH. TMPRSS6, a negative regulator of HAMP, is overexpressed in patients with NASH and HIF1? (hypoxia inducible factor-1) is downregulated. NAFLD patients with hepatic iron deposition exhibited higher hepcidin expression (3.1 fold, p = 0.04) but lower expression of cytokines. In conclusion, we observed elevated hepatic HAMP expression in patients with NASH and in NAFLD patients who had hepatic iron deposition, while proinflammatory cytokines displayed elevated expression only in patients with NASH, suggesting a regulatory role for hepcidin in NAFL to NASH transition and in mitigating inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28051796     DOI: 10.5604/16652681.1226818

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  9 in total

1.  HDL flux is higher in patients with nonalcoholic fatty liver disease.

Authors:  Arthur McCullough; Stephen F Previs; Jaividhya Dasarathy; Kwangwon Lee; Abdullah Osme; Chunki Kim; Serguei Ilchenko; Shuhui W Lorkowski; Jonathan D Smith; Srinivasan Dasarathy; Takhar Kasumov
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-09-10       Impact factor: 4.310

2.  Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease.

Authors:  Joel Marmur; Soheir Beshara; Gösta Eggertsen; Liselotte Onelöv; Nils Albiin; Olof Danielsson; Rolf Hultcrantz; Per Stål
Journal:  BMC Gastroenterol       Date:  2018-06-05       Impact factor: 3.067

3.  Development of a mouse iron overload-induced liver injury model and evaluation of the beneficial effects of placenta extract on iron metabolism.

Authors:  Akihiro Yamauchi; Akiko Kamiyoshi; Takayuki Sakurai; Hiroyuki Miyazaki; Eiichi Hirano; Hong-Seok Lim; Taiichi Kaku; Takayuki Shindo
Journal:  Heliyon       Date:  2019-05-10

Review 4.  Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack.

Authors:  Jarren R Oates; Melanie C McKell; Maria E Moreno-Fernandez; Michelle S M A Damen; George S Deepe; Joseph E Qualls; Senad Divanovic
Journal:  Front Immunol       Date:  2019-12-12       Impact factor: 7.561

5.  HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients.

Authors:  Amanda Fernández-Rodríguez; Salvador Resino; Óscar Brochado; Isidoro Martínez; Juan Berenguer; Luz Medrano; Juan González-García; María Ángeles Jiménez-Sousa; Ana Carrero; Víctor Hontañón; Jordi Navarro; Josep M Guardiola
Journal:  J Biomed Sci       Date:  2021-03-30       Impact factor: 8.410

6.  Combined Ultrasound Treatment with Transferrin-Coupled Nanoparticles Improves Active Targeting of 4T1 Mammary Carcinoma Cells.

Authors:  Xiangzi Jin; Jie Yu; Meijiao Yin; Amit Sinha; Guangming Jin
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

Review 7.  Iron overload disorders.

Authors:  Christine C Hsu; Nizar H Senussi; Kleber Y Fertrin; Kris V Kowdley
Journal:  Hepatol Commun       Date:  2022-06-14

8.  Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease.

Authors:  Zheng Xu; Fan-Wei Wu; Xuan Niu; Xiao-Peng Lu; Yan-Rong Li; Shu-Ting Zhang; Jun-Zhao Ou; Xue-Mei Wang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

9.  Hepcidin in morbidly obese women with non-alcoholic fatty liver disease.

Authors:  Teresa Auguet; Gemma Aragonès; Alba Berlanga; Salomé Martínez; Fàtima Sabench; Jessica Binetti; Carmen Aguilar; José Antonio Porras; Alicia Molina; Daniel Del Castillo; Cristóbal Richart
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.